Lipospheres represent a novel type of fat-based encapsulation system produced for the topical drug delivery of bioactive compounds. The goal of this research work was to develop lipospheres, including ketoprofen applied for topical skin drug delivery. Ketoprofen lipospheres were formulated by melt emulsification method using stearic acid and Phospholipon® 90G. The lipospheres were analysed in terms of particle size and morphology, entrapment efficiency, Differential scanning calorimetry, In-vitro drug release, In-vivo (Anti-inflammatory activity). Outcomes of research revealed that particle size was found to be 9.66 μm and entrapment efficiency 86.21 ± 5.79%. In-vivo, the study of ketoprofen loaded lipospheres formulation shows a higher plain formulation concentration in plasma (5.61 mg/mL). For dermis, ketoprofen retention was 27.02 ± 5.4 mg/mL for the lipospheres formulation, in contrast to that of the plain formulation group (10.05 ± 2.8 mg/mL). The anti-inflammatory effect of liposphere drug delivery systems was assessed by the xylene induced ear oedema technique and compared with marketed products. Finally, it seems that the liposphere drug delivery system possesses superior anti-inflammatory activity as compared to the marketed product gel consistencies. Liposphere may be capable of entrapping the medicament at very high levels and controlling its release over an extended period. Liposphere furnishes a proper size for topical delivery as well as is based on non-irritating and non-toxic lipids; it's a better option for application on damaged or inflamed skin.
Lipospheres were recorded as a particulate dispersion of solid spherical particles having a particle size ranging from 0.2-100 μm including a solid hydrophobic fat core of triglycerides or fatty acid derivatives which is stabilised by a phospholipid monolayer (Domb, 1990). Unsaturated fatty acids present in soybean phosphatidylcholine may be held responsible for increasing penetration capacity. The unsaturated fatty acids due to their packing nature, rupture the lipid structure of stratum corneum and hence increases the percutaneous penetration of drug moiety; furthermore, they intensively increase the fluidity of stratum corneum as well. Moreover, lecithin tends to have a greater affinity for epidermal tissue and seems to have the capability to improve skin hydration. The topically administered phospholipids are considered as safe due to their biodegradable nature and presence of natural body constituents (Kirjavainen et al., 1998). The internal core of lipospheres consists of the drug dispersed or dissolved in a solid fat matrix. Concerning lipospheres, the inconsistently found nomenclatures as nano-sized scale particles are known as solid lipid nanoparticles (SLN). These are being used in several drug deliveries like anti-inflammatory drug compounds, local anaesthetics, antibiotics, anticancer agents, vaccines, adjuvants and insect repellents (Amselem and Domb, 1996).

One of the best and most commonly used carriers of choice for topical drug delivery is lipospheres like stable lipid nanoparticles (SLN) due to their approved lipid components. i.e. their additives are used in commercially available topical cosmetics or pharmaceutical formulations. The smaller size of lipid particles promises close contact of the drug to the stratum corneum and may improve the fraction of drug penetrating the mucosa or skin. The important considerations like reduced systemic availability and increased drug stability can be achieved by controlled release through these carriers due to their solid lipid matrix (Souto et al., 2004).

Lipospheres carrier system promises various merits over other systems enlisted as physical stability (avoidance of coalescence), high entrapment efficiency for hydrophobic drugs, economic and reasonable cost of ingredients, easy to formulate and scale-up, high dispersion in the water medium, sustained or prolonged release of entrapped drugs, controlled particle size (Domb et al., 1996).

Ketoprofen falls under the broad classification of NSAID, which is most widely, serve as an analgesic, antipyretic and in the treatment of chronic and acute rheumatoid arthritis and osteoarthritis. Due to its adverse effect like gastrointestinal mucosa ulceration, it is avoided for its oral use, and thus better suited for transdermal drug delivery system (Cordero et al., 1997).

The goal of the work was proposed to formulate Ketoprofen Lipospheres for topical application to overcome the adverse effects resulting from its oral drug administration. The prepared lipospheres was characterised to validate its predefined properties, and anti-inflammatory activity was evaluated and compared with the current standard.

**MATERIALS AND METHODS**

Ketoprofen was provided as a generous gift sample from BEC Chemical, Mumbai, India (99% purity) stearic acid, xylene were purchased from Loba Chemicals Pvt. Ltd., and Himedia Lab Pvt. Ltd. Mumbai India, Soybean lecithin (Phospholipon® 90G) were purchased from Nattemann, Cologne, Germany (PC content 94–102%). Diethyl ether, disodium hydrogen phosphate, potassium dihydrogen phosphate and sodium chloride were purchased from Loba Chemicals Pvt. Ltd. and Himedia Lab Pvt. Ltd. Mumbai India. High-Performance Liquid Chromatography grade, Methanol and water purchased from Himedia Lab Pvt. Ltd. Mumbai, India. Dialysis membrane, 12.000 to 14.000 molecular weight cut off was purchased from Spectrum Laboratories Inc., Rancho Dominguez, and Canada. All other excipients were of analytical purity grade and used as received.

**Preparation of ketoprofen lipospheres (Melt Method)**

Lipid material of variant quantities (stearic acid), i.e. 200, 400 and 600 mg were used as the core material, and quantity weighed 200 mg of soybean phosphatidylcholine was utilised as the coating material. The corresponding core to coat ratio (Cr/Ct) was 1:1, 2:1 and 3:1, respectively. Ketoprofen was also used in various concentrations, i.e. 20 and 40 mg; core material was softening on a water bath. Then the required quantity of ketoprofen was dispersed into the lipidic melt. Phosphate buffered saline (PBS) 10 ml at 75°C was mixed with 200 mg of phospholipid. Uniform emulsion was obtained by homogenising a mixture by a magnetic stirrer for 15 minutes. The milky formulated emulsion was then rapidly cooled up to 20°C with a three-blade rotor continuously for the next 5 min for the formulation of homogeneous dispersion of lipospheres (Nasr et al., 2008).

**Determination of Entrapment efficiency**

About 40 mg of Lipospheres were accurately weighed and crushed with the help of glass mortar.
and pestle. Then the powdered Lipospheres were dispersed in 4 ml Phosphate Buffer having pH 7.4 and kept for 24 hrs. After that, the solution was filtered, and the filtrate was analysed for the drug content (Iannuccelli et al., 2006). The formula calculated the entrapment efficiency of the drug:

\[
\text{Percentage encapsulation efficiency} = \frac{\text{Practical drug content}}{\text{Theoretical drug content}} \times 100
\]

**Characterisation of Ketoprofen Lipospheres**

**Electron microscopy**

By using Scanning Electron Microscopy (SEM) (JELO 5400, Japan), a complete study of surface characteristics of the selected ketoprofen lipospheres formulation were analysed. The samples for SEM were prepared by lightly sprinkling the lipospheres powder on a double adhesive tape which stuck to an aluminium stub. The stubs were then coated with gold to a thickness of about 300Å using a sputter coater.

**Particle size analysis**
Table 1: The Optimisation of Different Lipospheres Preparation, Entrapment Efficiency Percentages, Particle Size of Different Lipospheres Preparations (Mean ± Sd, N = 3)

| Batch code | Core / coat ratio | Amount of drug (mg) | Stirring rate (rpm) | Entrapment efficiency per cent ± SD | Particle size (μm) |
|------------|------------------|---------------------|--------------------|------------------------------------|-------------------|
| F1         | 1:1              | 20                  | 650                | 81.12±0.21                         | 12.39             |
| F2         | 1:1              | 20                  | 700                | 82.02±1.23                         | 11.13             |
| F3         | 1:1              | 20                  | 750                | 83.98±2.04                         | 9.08              |
| F4         | 1:1              | 40                  | 650                | 82.50±3.01                         | 13.21             |
| F5         | 1:1              | 40                  | 700                | 83.76±1.23                         | 11.01             |
| F6         | 1:1              | 40                  | 750                | 84.01±5.12                         | 9.05              |
| F7         | 2:1              | 20                  | 650                | 80.01±3.41                         | 13.02             |
| F8         | 2:1              | 20                  | 700                | 81.21±3.08                         | 12.78             |
| F9         | 2:1              | 20                  | 750                | 83.65±0.78                         | 10.04             |
| F10        | 2:1              | 40                  | 650                | 84.23±3.01                         | 12.65             |
| F11        | 2:1              | 40                  | 700                | 86.21±5.79                         | 9.66              |
| F12        | 2:1              | 40                  | 750                | 86.09±1.65                         | 9.42              |
| F13        | 3:1              | 20                  | 650                | 79.45±2.85                         | 17.08             |
| F14        | 3:1              | 20                  | 700                | 81.78±1.04                         | 15.47             |
| F15        | 3:1              | 20                  | 750                | 82.09±2.38                         | 14.04             |
| F16        | 3:1              | 40                  | 650                | 81.92±0.69                         | 19.12             |
| F17        | 3:1              | 40                  | 700                | 82.57±1.49                         | 16.09             |
| F18        | 3:1              | 40                  | 750                | 83.36±3.21                         | 15.01             |

Table 2: Skin Permeation Parameters of Plain Formulation and Ketoprofen Loaded Formulation

| Sr. no. | Formulation | Transdermal flux | Enhancement ratio | Permeation coefficient |
|---------|-------------|------------------|-------------------|------------------------|
| 1       | plain formulation | 4.95         | 1.00             | 4.95 × 10⁻⁴           |
| 2       | ketoprofen loaded formulation | 8.053        | 1.62             | 8.053 × 10⁻⁴           |

Table 3: Pharmacokinetic Parameters For In Vivo Permeation Study

| Pharmacokinetic parameter | Unit     | Ketoprofen loaded lipospheres | Plain formulation |
|---------------------------|----------|------------------------------|-------------------|
| AUC O₁₂                   | h mg/l   | 22.878                       | 4.267             |
| AUC O∞                    | h mg/l   | 23.667                       | 5.743             |
| Tₚₙₙ                    | h        | 5                            | 8.321             |
| Cₘₙₙ                    | mg/l     | 5.612                        | 1.32              |
| MRT O₁₂                  | h        | 6.213                        | 8.562             |
| MRT O∞                  | h        | 6.542                        | 9.351             |
Calibrated stage micrometre method is used to calculate the size of liposphere formulation, 10x lance compound microscope is used for it. Dried lipospheres were firstly re-suspended in distilled water and located in a glass slide using a stage micrometre, the number of division of calibrated eyepiece was counted.

**Differential scanning calorimetry (DSC)**

Ketoprofen sample, soya lecithin and drug-loaded lipospheres of the selected formulation were analysed by differential scanning calorimeter (DSC) which was carried out by heating the sample from 30°C to 400°C at the heating rate of 10°C/min, in a nitrogen environment (nitrogen gas flow rate of 60.0ml/min). The differential scanning calorimetry was conducted on NETZSCH DSC 200F3 240-20-427-L Proteus Software.

**High Performance Liquid Chromatography analysis of ketoprofen lipospheres**

High Performance Liquid Chromatography (HPLC) system for ketoprofen lipospheres consisted of an ultraviolet lamp (190-800), and a diode array detector. A 4.6 mm ID × 250 mm (5µm) Zorbax SB-C18 column (Agilent Carry 1220, USA) was utilised. Methanol and water (45:44 v/v) are used as a mobile phase at a flow rate of 1.1 ml/min. The analysis was carried out by absorbance at 259 nm.

**In-vitro release of ketoprofen from lipospheres**

Dialysis tube (MWCO 2000 Da) was used for the study of the release of drug equilibrated at temperature 37 ± 0.5 °C, 100 rpm speed. Ten milligrams of liposphere were placed into the beaker containing 2 ml phosphate buffer (PH 7.4) and kept in a dialysis tube. For complete separation of the drug in phosphate-buffered saline, the dialysis tube was kept in 50 ml of aqueous recipient phosphate-buffered saline (PBS) medium having pH 7.4 with continuous agitation at 100 rpm and 37±2 °C. At a suitable time interval, the complete PBS medium was replaced with the required volume of fresh PBS medium and samples were characterised by high performances liquid chromatography (Agilent Cary 1220).

**In-vitro permeation study**

**Table 4**: Anti Inflammatory Activity of Placebo And Ketoprofen Loaded Lipospheres Compared To The Marketed Gel (Mean ± Sd, N = 3)

| Group                          | Dose            | Ear thickness (µm) | 2 hrs after treated inflammation | % inflammation inhibition |
|-------------------------------|-----------------|-------------------|----------------------------------|--------------------------|
| Control saline (Group – 1)    | (Saline) water 10 ml | 148±3.6           | 180±3.6                          | 0                        |
| Plain drug (Group – 2)        | Cream 20 mg     | 147±3.1           | 171±3.1                          | 25                       |
| Ketoprofen lipospheres (Group -3) | Cream 40 mg     | 148±1.7           | 158±2.1                          | 68                       |
| Marketed product (Group -4)   | Gel 100 mg      | 149±2.3           | 160±1.2                          | 65                       |

© International Journal of Research in Pharmaceutical Sciences 1857
lation and plain formulation is estimated from the slope of the linear portion of the cumulative quantity permeated within the skin per unit surface area Vs time plot.

Permeation availability examination of BUD

As it has been mentioned above the conditions feeding management of the rat is the same. Before performing a study, the dorsal skins of albino rat is cleaned with a physiological saline solution after taking away the hairs, approximately before 24 hours. Firstly 0.6 ml of ketoprofen loaded lipospheres is applied on the dorsal surface of albino rat and after that simple formulation is used on the dorsal surface (3.14 cm²) on another rat. One ml of blood sample is taken at fixed intervals of time (0.5, 1, 2, 3, 6, 9 and 12 hrs) by retro-orbital puncture, the blood samples were centrifuged at 4000 rpm for 5 minutes, and plasma is obtained from the supernatant. After performing the above procedure, the rat is to be made sacrificed and the administrated skin so collected is appropriately stripped.

To eliminate the ketoprofen remains on the surface, the excised skin is appropriately and thoroughly washed with alcohol and water. Further separate epidermis and dermis a heat separation membrane is to be performed (Kligman, 1963). After, samples of the skin are applied on a large watch glass (60 ± 1°C) for 2 minutes, and by using a dull scalpel blade, the epidermis is scraped from the skin. The sample pieces of the dermis or epidermis are correctly mixed with physiological saline solution (1 ml) and allowed for homogenisation for 3 minutes. The quantity of ketoprofen in the dermis, epidermis or blood samples is studied by using high-performance liquid chromatography, respectively.

In-vivo study

Anti-inflammatory study of lipospheres

Animal handling

The National Institute of Health Guide for the use and care of Laboratory Animals approved by the Institutional Ethical Committee was adopted for this research. Ethical Committee registration no. is 147/PO/a/11/CPCSEA.

120 to 200-gram albino rats of both sexes which are acclimatised within the animal facility of Guru Ramdas Khalsa Institute of Pharmacy, Jabalpur; Madhya Pradesh were kept in standard cages where they are feed and taken care on standard animal pellets (obtained from Nuvita Feed Ltd., Kampala) and water ad libitum.

An albino rat for antipyretic activity measurements, CTO 12667 electronic probe thermometers are used for measurement of basal anal temperature, which should be exceeding 37°C. For the study of anti-inflammatory activity, albino rats were randomly classified into four groups and made free with access to water and food overnight.

Xylene induced ear oedema

Before inducing inflammation, i.e. oedema, the thickness of the right ear of every albino rat is measured using vernier callipers. Inflammation was induced 30 minutes after dose administration by applying 0.05 ml of xylene by employing a microliter pipette (Transferpette®, Germany) through the ear veins until the inner and outer surface of the ear was complete moistened (Kou et al., 2005).

Every albino rat was etherised 2 hours later for anaesthesia by using diethyl ether and therefore, the analysis of the inflamed ear thickness repeated. The thickness of the ear as the reference of anti-inflammation was referred to calculate the extent of inhibition (Akindele and Adeyemi, 2007). Group one saline, group second direct drug, third group formulation on ketoprofen loaded lipospheres, and group fourth marketed product. The experimental procedure was similar in the analysis of the formulated product; Percentage anti-inflammatory inhibition was measured as:

\[
\frac{(\Delta T_p - \Delta T_s/t)}{\Delta T_p} \times 100
\]

\(\Delta T_p\): Mean change in ear thickness of the placebo group.

\(\Delta T_s/t\): Mean change in ear thickness of standards or test group.

RESULTS AND DISCUSSION

Lipospheres shows a promising lipid-based topical drug carrier system, including a lipid core stabilised by a layer of phospholipid coat encapsulated in their surface. Various formulation variables have been found to affect the drug embedment inside the lipospheres as well as its drug release profile. As the concentration of lipid particle size was increased, then drug enclosing efficiency of lipospheres was decreased. Moreover, the enhanced concentration of lipid affects the size of the particles and hardly may decrease the encapsulated capacity but not significantly. The lipid concentration, increase in particle size due to increase viscosity of emulsion bigger droplets were formed. But increasing the concentration of lipid, drug entrapment capacity of lipospheres was decreased (Quintanar-Guerrero et al., 1996).

The amount of drug is considered to be held responsible for altering the entrapment efficiency of its
own and particle size of the lipospheres. As increased in the size of the particle of ketoprofen, liposphere increases the quantity of the drug. The entrapment effectiveness of medication basically in increment partly with a progressive increase in the quantity of drug but, appreciably decreases to, further because of the way that the proportion of medication to the lipid network at some degree increments and as a consequence to be had area for the medication to be entrapped is reduced. It is viewed as that the bad aqueous solubility of medication is pretty helping accountable for its excessive entanglement performance in hydrophobic centres (Barakat and Yassin, 2006).

Stirring velocity negatively affect the particle length (i.e., as the mixing speed expanded, the molecule size diminished). As the stirring velocity turned into increased, the length of the microdroplet of the emulsion turned into reduced ensuing with inside the formation of smaller length microparticles. These findings are much like the ones reported previously (Aberturas et al., 2002). As the agitation rate increases from 650 to 750 rpm, the particle size of the ketoprofen lipospheres was decreased. So it turned into covered that the particle size of lipospheres turned into managed through agitation rate. This turned into because of the smaller emulsion globules created through a better agitation speed ended in unpredictable formed lipospheres, which furnished greater energy to dispense the oil phase in water, however better stirring rate.

But latter enhancing agitation speed, lump formation due to aggregates of lipospheres. The drug entrapment efficiency increased. The drug entanglement effectiveness enhances because of increment in useful surface area on the decrease of the lipospheres size. The stirring rate of 750 rpm F11 was found to be the optimum parameter for ketoprofen lipospheres, as the drug entrapment efficiency were good high, i.e. 86.21 ± 5.79 % at this stirring rate. After optimisation study, it was found that the formulation F11 has higher entrapment efficiency and small particle size. Thus formulation F11 was selected for further study.

Electron microscopy

Figure 1 illustrates the SEM of freshly prepared ketoprofen lipospheres. It is revealed that the drug-loaded lipospheres are round in shape. Lipospheres formulated including an excessive quantity of the lipid (drug: lipid ratio) displayed smoother surfaces than those formulated taking a lesser quantity of the lipid. However, irregular surfaces and a small length of the lipospheres have been found for the ones formulated with a decrease quantity of the lipid. When phosphatidylcholine is utilised as a coat, then the resultant particle obtained as a round in shape with the irregular surface (Tursilli et al., 2006).

Analysis of particle size

Results shown in Table 1 reveal that the mean size of the particle for lipospheres extended from 9.65 μm F11 which allow them, appropriate applicants, for a topical route. Lipospheres formulated the usage of Cr.Ct proportion. In any case, by expanding Cr.Ct from 1:1, 2:1 and 3:1 increment with inside the mean particle size. Domb et al. acquired comparable outcomes. They expressed that the common particles size increments with expanding fat to phospholipid molar proportion (Domb et al., 1996) which might be attributed to the expanded consistency of the emulsion formed because of higher measure of lipid utilised in the formulation. By further review of the information screen that was increasing the number of drug services for the formulation of lipospheres, from 20 and 40 mg was went with an expansion in the size of the particle. Comparable outcomes were additionally acquired with ketoprofen lipospheres (Bekerman et al., 2004).

Differential scanning calorimetry

Formula F11 was picked as a delegate of ketoprofen lipospheres because it possessed the best entanglement effectiveness. Pure ketoprofen exothermic peak was found 98°C (Figure 2a). The exothermic peak of the pure soy lecithin was observed at 124.8°C (Figure 2b).

The exothermic peak of lipospheres was found between 65 to 97°C and maximum at 122°C (Figure 2c). In this way, it may be inferred that ketoprofen in the lipospheres was in the crystalline section of a molecular dispersion or a solid solution state in the matrix of lipid. Differential scanning calorimetry i taken into consideration as a device to research the melting actions of crystalline substances such as solid lipid nanoparticles (Hou et al., 2003).

In-vitro release of ketoprofen from lipospheres

The release of ketoprofen from the liposphere sown in Figure 3 shows sustain release characteristics in formulation F11 than different formulations, and the entanglement effectiveness is greater in this formulation on account of diminished particle size. The lipospheres produced via melt method constituting more quantity of drug in their lipid core results in a phospholipid bilayer. Solid cores rich in the drug are regarded to expose the sustained-release character of medication (Lippacher et al., 2001).

Stearic acid provides the highest T-24 hrs value. It may justify the fact that the hydroxyl group present in stearic acid is accountable for making the
matrix more susceptible for hydration in dissolution medium and subsequently giving a hydrophilic pathway to a water molecule to arrive at the medication and change the disintegration rate (El-Gibaly and Abdel-Ghaffar, 2005).

Permeation availability examination of BUD

To study in-vitro skin permeation on Franz diffusion cells with an effective diffusional area of 3.12 cm² is used. Skin Permeation Parameters of Plain Formulation and Ketoprofen Loaded Formulation are shown in Table 2. An initial amount of ketoprofen in the donor rooms is the same, and flux rates of ketoprofen resulted from permeation experiments is shown in Figure 4. It has been observed that the flux rate of ketoprofen liposphere formulation is significantly higher in quantity than that from the simple formulation. There was no lag time shown in the permeation of ketoprofen loaded liposphere, but that of the control has shown a lag time of 1 hrs. Therefore it indicates that permeation followed the zero-order release kinetics and the steady-state flux (Js) of the simple formulation was 4.95 mg cm⁻² h⁻¹.

In contrast, that of ketoprofen loaded liposphere formulation was 8.053 mg cm⁻² h⁻¹, respectively. The difference in the significant permeation may also depend on the property and nature of the carrier. After application, the skin surface is covered by a film of ketoprofen loaded liposphere. The oppressed cover makes drug carrier instantly accessible to the skin, which facilitates drug permeation across the stratum corneum.

Moreover, the lecithin in the formulation may also play a role since it can interact with the skin, joining lipid bilayer and loosening intercellular regions between corneocytes (Sinico et al., 2005). This can be adequately and clearly explained by the ability of plain formulation in increasing skin hydration, which well alimentally results in swelling and opening stratum corneum with time (Zhai and Maibach, 2001).

In-vivo permeation study

The intention of In-vivo permeation investigation of ketoprofen loaded liposphere is to verify the plausibility of delivery ketoprofen into the blood via the skin. It is evident from the figure that the dispensing of the liposome formulation has contributed are remarkable ketoprofen concentration were as ketoprofen has shown a much lower concentration for the plain. In Table 3, the pharmacokinetic parameter for in-vivo penetration observe is being shown. As it has been shown that the ketoprofen loaded lipospheres formulation has given better concentration of plasma (5.61 mg/l) when contrasted with the plain formulation (1.32 mg/l). The plasma AUC (0 – t) of ketoprofen loaded lipospheres formulation was 22.87 h mg/l, which is altogether larger in amount than that of the plain formulation (4.267 h mg/l) (P < 0.05). This outcome has been gotten because of the nearby contact between stratum corneum and liposphere formulation. By framing an occlusive film on pores and skin surface, the drawn-out hydration of skin is kept up by lipospheres formulation, which gives the stratum corneum a compact structure opens up and assisting in most excellent penetration of ketoprofen into the blood via the pores and skin (Kawadkar et al., 2013).

The total quantities of ketoprofen in dermis and epidermis are being studied the residual ketoprofen inside the skin (Figures 5 and 6). As it has been very clearly shown that ketoprofen content which has been deposited in the epidermis for liposphere formulation ranged 4 to 6 mg/ml, with no appropriate substantial fluctuation; however at the other ketoprofen level form the plain formulation group expanded radically, even as much as 13.81 mg/ml at 12 hrs. For dermis, the ketoprofen held was 27.02 ± 5.4 mg/ml for the lipospheres formulation, manifestly notable than that of the plain formulation set (10.05 ± 2.8 mg/ml).

Although elevated level in the epidermis is being achieved the generally low level in the dermis for plain formulation solution has just demonstrated the restriction in transferring ketoprofen into deep skin, not to mention blood course. It will also be stated that for distinction in permeability between tests set the distinctive function mode will also be responsible. Closed interaction between lipospheres formulation and the stratum corneum and the small size may be the possible motive why lipospheres formulation can boom ketoprofen infiltrating into the feasible skin, even into the bloodstream. It has been stated in a preceding examine that fluorescence-categorised nanoparticles at a length of 70 nm passed the skin hindrance an is likewise noticeable in the deeper skin layer, which is beneath the stratum corneum layer, wherein as bigger size particles of 700 nm in diameter measurement as proven no penetration (Lademann et al., 2011).

Hence ketoprofen lipospheres formulation acquired in examination with small diameter good very easily and closely contacts to the skin surface and form attachment of meagre films on the skin, improving the entrance of ketoprofen. Thus, it’s been certainly proved that so that you can yield fluxes, ketoprofen in the benchmark group ought to permeate freely.

In-vivo anti-inflammatory study
Xylene induced ear oedema

Formulation F11 of lipospheres was given in forms, cream textures as it was affirmed that the presence of a matrix of solid particles with a size in the range of micrometre forms a semi-solid dispersion having the suitable consistency for a topical utility which represents an alternative medication carrier system to emulsions and polymeric nanoparticles (Lippacher et al., 2002). As evident in Table 4, variations among the anti-inflammatory activity of the saline control and plain medication had been additives that possess no in-vivo anti-inflammatory activity.

The thickness of the ear as the index of anti-inflammation was used to measure the extent of inhibition. Group one saline, group second plain drug, group thread formulation on ketoprofen loaded lipospheres cream, and group fourth marketed product. Percentage of anti-inflammatory inhibition was calculated. Anti-inflammatory % inhibition of plain drug, ketoprofen loaded lipospheres cream and Marketed Rhofenid Sodium Gel was found to be 25%, 68% and 65%. Ketoprofen lipospheres possess good anti-inflammatory activity as compared to marketed preparation.

The lipospheres scattering stayed more prominent to the promoted item in its capacity to suppress oedema beginning from the second hour and all through the entire investigation time proposing the supported calming action of ketoprofen lipospheres. The occlusive impact of the lipospheres can also advance the entry of actives into the pores and skin (Souto et al., 2005). It is significant for a medication that it ought to sustained release for a prolonged duration of time (Mei, 2003).

As a rule, the high explicit surface territory of the submicron-sized lipospheres helps contact of encapsulated drugs with the stratum corneum ensuring in sustained arrival of the drug for an extensive-time period. It has been recently detailed that the in-vivo lipospheres distribution shows an excessive affinity to infected tissue wherein they’re properly appropriate for being primarily based totally on non-toxic and non-irritant lipids (Cortesi, 2002). Mixing of phospholipid particles with the pores and skin lipids may be held reliable for altering the characteristics of the keratinised layer. It may have served in addition to maintain the drug molecules inside the skin, consequently main to the extended presence of drug molecules (Bhatia et al., 2004) . The drug in its lipo-solubilised state may have determined facilitated entry into the extreme barrier comprising of stratum corneum.

CONCLUSION

From the above data, it is concluded that ketoprofen drugs are suitable in lipospheres, and it can also be considered a promising delivery system for this drug. Liposphere can be able to entrap the drug at very high levels and sustain its release over an extended time. Liposphere possess a suitable size for topical route and is based on non-irritative and non-toxic lipids, and it is perfectly suited on damaged or inflamed skin. As compared to the market product, lipospheres have high stability as well as superior anti-inflammatory.

ACKNOWLEDGEMENT

Authors are highly thankful for Mr Dipesh Mehta officer in charge (SEM, DSC) Diya lab (Mumbai, Maharashtra) for assisting in analytical studies. BEC Chemical (Mumbai, India), for providing the gift sample of Ketoprofen and Phospholipid GmbH and Köln, Germany for providing a sample of Phospholipon® 90H.

Funding Support

The authors declare that they have no funding support for this study.

Conflict of Interest

The authors declare that there is no conflict of interest for this study.

REFERENCES

Aburturas, M. R., Molpeceres, J., Guzmán, M., García, F. 2002. Development of a new cyclosporine formulation based on poly(caprolactone) microspheres. Journal of Microencapsulation, 19(1):61–72.

Akindele, A. J., Adeyemi, O. O. 2007. Anti-inflammatory activity of the aqueous leaf extract of Byrsocarpus coccineus. Fitoterapia, 78(1):25–28.

Amselem, S., Domb, A. J. 1996. Liposphere delivery systems for vaccines. Microparticulate Systems for Drug Delivery. Marcel Dekker, pages 149–68.

Barakat, N. S., Yassin, A. E. B. 2006. In Vitro Characterization of Carbamazepine-Loaded Pecific Lipospheres. Drug Delivery, 13(2):95–104.

Bekerman, T., Golenser, J., Domb, A. 2004. Cyclosporin Nanoparticulate Lipospheres for Oral Administration. Journal of Pharmaceutical Sciences, 93(5):1264–1270.

Bhatia, A., Kumar, R., Katare, O. P. 2004. Tamoxifen in topical liposomes: development, characterisation and in-vitro evaluation. J Pharm Pharm Sci, 7(2):252–259.
Bunjes, H., Koch, M. H. 2005. Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles. *Journal of Controlled Release*, 107(2):229–243.

Chen, S., Liu, W., Wan, J., Cheng, X., Gu, C., Zhou, H., Chen, S., Zhao, X., Tang, Y., Yang, X. 2013. Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique. *Drug Development and Industrial Pharmacy*, 39(1):20–28.

Cordero, J. A., Alarcon, L., Escribano, E., Obach, R., Domenech, J. 1997. A Comparative Study of the Transdermal Penetration of a Series of Nonsteroidal Antiinflammatory Drugs. *Journal of Pharmaceutical Sciences*, 86(4):503–508.

Cortesi, R. 2002. Production of lipospheres as carriers for bioactive compounds. *Biomaterials*, 23(11):2283–2294.

Domb, A. J. 1990. Lipospheres for controlled delivery of pharmaceuticals, pesticides and fertilisers. *Nova Pharmaceutical Corp*, 79:8–11.

Domb, A. J., Bergelson, L., Amselem, S. 1996. Lipospheres for controlled delivery of substances. *Drugs and the Pharmaceutical Sciences*, 73:377–410.

El-Gibaly, L., Abdel-Ghaffar, S. K. 2005. Effect of hexacosanol on the characteristics of novel sustained-release allopurinol solid lipospheres (SLS): factorial design application and product evaluation. *International Journal of Pharmaceutics*, 294(1-2):33–51.

Hou, D. Z., Xie, C. S., Huang, K. J., Zhu, C. H. 2003. The production and characteristics of solid lipid nanoparticles (SLNs). *Biomaterials*, 24(10):1781–1785.

Iannuccelli, V., Sala, N., Tursilli, R., Coppi, G., Scalia, S. 2006. Influence of liposphere preparation on butyl-methoxydibenzoylmethane photostability. *European Journal of Pharmaceutics and Biopharmaceutics*, 63(2):140–145.

Kawadkar, J., Pathak, A., Kishore, R., Chauhan, M. K. 2013. Formulation, characterization and in vitro-in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. *Drug Development and Industrial Pharmacy*, 39(4):569–578.

Kirjavainen, P. V., Ouwehand, A. C., Isolauri, E., Salminen, S. J. 1998. The ability of probiotic bacteria to bind to human intestinal mucus. *FEBS Microbiology Letters*, 167(2):185–189.

Kligman, A. M. 1963. Preparation of Isolated Sheets of Human Stratum Corneum. *Archives of Dermatology*, 88(6):702–702.

Kou, J., Ni, Y., Li, N., Wang, J., Liu, L., Jiang, Z. H. 2005. Analgesic and Anti-inflammatory Activities of Total Extract and Individual Fractions of Chinese Medicinal Ants Polythrichis lamellidens. *Biological & Pharmaceutical Bulletin*, 28(1):176–180.

Lademann, O., Kramer, A., Richter, H., Patzelt, A., Meinke, M. C., Roewert-Huber, J., Czaika, V., Weltmann, K. D., Hartmann, B., Koch, S. 2011. Antisepsis of the follicular reservoir by treatment with tissue-tolerable plasma (TTP). *Lasers Physics Letters*, 8(4):313–317.

Lippacher, A., Müller, R. H., Mäder, K. 2001. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. *International Journal of Pharmaceutics*, 214(1-2):9–12.

Lippacher, A., Müller, R. H., Mäder, K. 2002. Semisolid SLNTM dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. *European Journal of Pharmaceutics and Biopharmaceutics*, 53(2):155–160.

Mei, Z. 2003. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. *European Journal of Pharmaceutics and Biopharmaceutics*, 56(2):189–196.

Nasr, M., Mansour, S., Mortada, N. D., Shamy, A. A. E. 2008. Lipospheres as Carriers for Topical Delivery of Aceclofenac: Preparation, Characterization and In Vivo Evaluation. *AAPS PharmSciTech*, 9(1):154–162.

Quintana-Guerrero, D., Fessi, H., Allémann, E., Doelker, E. 1996. Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. *International Journal of Pharmaceutics*, 143(2):133–141.

Sinico, C., Manconi, M., Peppi, M., Lai, F., Valenti, D., Fadda, A. M. 2005. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction. *Journal of Controlled Release*, 103(1):123–136.

Souto, E. B., Müller, R. H., Gohla, S. 2005. A novel approach based on lipid nanoparticles (SLN®) for topical delivery of α-lipoic acid. *Journal of Microencapsulation*, 22(6):581–592.

Souto, E. B., Wissing, S. A., Barbosa, C. M., Müller, R. H. 2004. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. *International Journal of Pharmaceutics*, 278(1):71–77.

Tursilli, R., Casolari, A., Iannuccelli, V., Scalia, S. 2006. Enhancement of melatonin photostability by encapsulation in lipospheres. *Journal of Pharm-
Zhai, H., Maibach, H. I. 2001. Effects of Skin Occlusion on Percutaneous Absorption: An Overview. *Skin Pharmacology and Physiology*, 14(1):1–10.